Every 8-K that Pacific Biosciences of California, Inc. (PACB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PACB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PACB filings page.
Pacific Biosciences of California, Inc. reported second-quarter 2026 revenue of $39.0 million, slightly below $39.8 million a year earlier. GAAP gross margin was 32% and non-GAAP gross margin 36%. GAAP net loss was $44.7 million, or $0.14 per share, and non-GAAP net loss was $41.9 million, or $0.14 per share. Cash, cash equivalents and investments were $236.9 million at June 30, 2026. The company expects full‑year 2026 revenue of $155 million to $165 million.
On July 30, 2026, the board approved a restructuring plan with a Reduction in Force of about 40 employees, approximately 8% of the workforce. Including related non‑headcount actions, PacBio expects to lower annualized operating expenses by $30 million to $40 million by the end of 2027 and incur about $2.0 million of pre‑tax charges, largely in the third quarter of 2026.
The board appointed Mark Van Oene as President and Chief Executive Officer and a director effective August 5, 2026, succeeding Christian Henry, who remains on the board and will serve as Senior Business Advisor through December 31, 2026. Van Oene’s employment terms include a $743,000 base salary, a target bonus equal to 100% of salary, and equity awards with grant-date values of $1,687,500 in stock options and $562,500 in RSUs. Henry’s transition agreement provides monthly salary of $12,907.62 during the transition, a potential 2026 incentive based on a $154,891.40 target, and a lump-sum payment of $1,161,685.50 subject to a separation agreement.
Pacific Biosciences of California, Inc. reported that board member Christopher M. Smith resigned from the company’s board of directors, effective immediately on July 8, 2026. The company stated it is not aware of any disagreement with Mr. Smith regarding its operations, policies, or practices that led to his resignation.
Pacific Biosciences of California, Inc. reported results of its annual stockholder meeting and approval of an equity plan change. Stockholders approved an amendment to the 2020 Equity Incentive Plan, adding 16,000,000 shares of common stock reserved for future equity awards, following prior Board approval.
At the June 3, 2026 meeting, holders of 203,009,375 shares, about 65% of the 310,487,099 shares outstanding as of April 6, 2026, were represented. Stockholders elected Class III directors, ratified Ernst & Young LLP as auditor for 2026, approved named executive officer compensation on an advisory basis, and confirmed the equity plan amendment.
Pacific Biosciences of California, Inc. reported first quarter 2026 revenue of $37.2 million, flat year over year, with stronger consumables offset by weaker instrument sales. Consumable revenue rose to $21.8 million from $20.1 million, while instrument revenue declined to $9.7 million from $11.0 million.
GAAP gross margin improved to 35% from negative 4% a year ago, and GAAP net loss narrowed sharply to $8.3 million from $426.1 million, helped by restructuring actions and a gain on disposing short-read sequencing assets. Non-GAAP net loss improved to $35.9 million from $44.4 million.
The company completed the sale of short-read assets for net cash proceeds of about $48.1 million, ending the quarter with $276.0 million in cash, cash equivalents, and investments. Management expects full-year 2026 revenue between $165 million and $175 million, supported by growing clinical adoption of HiFi sequencing and an expanded SPRQ-Nx rollout.
Pacific Biosciences of California, Inc. disclosed two developments. First, Chief Accounting Officer Michele Farmer will voluntarily resign effective March 21, 2026, to pursue another opportunity. The company states her departure is not related to any disagreement over operations or accounting, and she will not receive severance. Chief Financial Officer Jim R. Gibson will also serve as principal accounting officer, with no change to his compensation.
Second, on March 5, 2026, the company signed a binding term sheet with Personal Genomics of Taiwan, Inc. It provides a worldwide, royalty-free, non-exclusive license to U.S. Patent No. 7,767,441 and related patents, plus a five-and-a-half-year covenant not to sue under PGI patents, and dismissal of all litigation between the parties. Pacific Biosciences will make fixed payments of $8,000,000 in the first quarter of 2026 and $5,000,000 in the first quarter of each of 2027, 2028 and 2029, with the 2027 payment increasing by $1,000,000 if 2026 revenue reaches $165,000,000 and by another $1,000,000 if it reaches $180,000,000.
Pacific Biosciences of California, Inc. appointed Christopher Gibson, Ph.D., to its Board of Directors as a Class I director effective March 3, 2026, expanding the board to ten members. His initial term runs until the 2026 annual meeting, and he will also serve on the Science and Technology Committee.
Dr. Gibson co-founded and chairs Recursion, a clinical-stage biotechnology company known for its AI-driven drug discovery platform that combines large-scale biological data with machine learning. PacBio highlights his background in integrating automation, high‑dimensional biology and artificial intelligence as directly relevant to its strategy of pairing HiFi long-read sequencing with advanced analytics.
The company states there are no related-party transactions or family relationships involving Dr. Gibson that require disclosure, and he will receive compensation under PacBio’s standard non‑employee director policy along with the company’s standard indemnification agreement. A press release dated March 5, 2026, further describes his appointment and PacBio’s view that AI-enabled data tools are increasingly important as sequencing datasets grow.
Pacific Biosciences of California, Inc. reported mixed fourth-quarter and full-year 2025 results, combining solid revenue growth with large GAAP losses driven by restructuring and non-cash charges. Q4 2025 revenue rose to $44.6 million from $39.2 million, with full-year 2025 revenue edging up to $160.0 million from $154.0 million. Consumables were a key driver, reaching $21.6 million in Q4 and $82.0 million for 2025, while instrument revenue declined year over year on a full-year basis.
Non-GAAP gross margin improved to 40% for both Q4 and 2025, up from 31% and 33% in the prior-year periods, reflecting better underlying profitability. Yet GAAP net loss widened to $546.4 million for 2025 from $309.9 million, largely due to restructuring, impairment, amortization and the absence of a prior-year $154.4 million debt restructuring gain. Non-GAAP net loss improved to $158.8 million from $228.0 million, and year-end cash, cash equivalents and investments were $279.5 million. The company also completed the sale of short-read sequencing assets for net proceeds of about $48.1 million and highlighted collaborations and product innovations aimed at long-read sequencing growth.
Pacific Biosciences of California, Inc. reported an internal, interim reassignment of executive responsibilities. Effective January 28, 2026, Chief Operating Officer Mark Van Oene now oversees the company’s sales and customer support teams, duties that were previously handled by President and Chief Executive Officer Christian Henry.
At the same time, Mr. Henry has temporarily taken over responsibility for operations and research and development, which had been under Mr. Van Oene. Both executives keep their existing roles and core duties, and the company states there will be no changes to their titles or compensation in connection with this shift.
Pacific Biosciences of California, Inc. completed an asset sale to Illumina Cambridge Limited, transferring intellectual property and other assets tied to its short-read DNA sequencing and related reagent and detection technologies. The buyer paid $50.0 million in cash and assumed certain liabilities.
PacBio also received a non-exclusive license back to some of the sold intellectual property, allowing continued access to those technologies. At PacBio’s direction, the buyer will pay 4% of the net proceeds from the purchase price to former Apton Biosystems equity holders in connection with waived milestones, leaving PacBio with approximately $48.1 million in net cash proceeds from the transaction.
Pacific Biosciences of California, Inc. filed a current report to highlight a business update and unaudited preliminary financial results for the quarter and year ended December 31, 2025. The company issued a press release that includes preliminary revenue estimates and a preliminary balance of cash, cash equivalents and investments as of December 31, 2025.
Portions of the press release that cover these preliminary figures and the forward-looking statements section are treated as filed under the "Other Events" section, while the broader business update and results discussion are furnished under results-of-operations disclosure rules. The company notes that its financial statements for this period are not yet finalized or audited and may change materially, and cautions readers not to place undue reliance on the preliminary information.
Pacific Biosciences of California, Inc. reported that it announced financial results for its third fiscal quarter ended September 30, 2025. The company disclosed that these third-quarter 2025 results, covering its results of operations and financial condition, are presented in a press release titled “PacBio Announces Third Quarter 2025 Financial Results.”
The press release is furnished as Exhibit 99.1 to this report, meaning it provides the detailed quarterly figures and commentary, while the report itself primarily serves to formally notify investors that the results have been released.